Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Japanese Journal of Ophthalmology
Published in: Japanese Journal of Ophthalmology 4/2012

01-07-2012 | Clinical Investigation

Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety

Authors: Veysi Öner, Fatih Mehmet Türkcü, Mehmet Taş, Mehmet Fuat Alakuş, Yalçın İşcan

Published in: Japanese Journal of Ophthalmology | Issue 4/2012

Login to get access

Abstract

Purpose

To evaluate the efficacy and safety of loteprednol etabonate (LE) 0.5 % in vernal keratoconjunctivitis (VKC) patients compared to prednisolone and fluorometholone.

Methods

The patients were randomized into three groups: the loteprednol group, prednisolone group and fluorometholone group. Medications were administered four times daily, for a total of 28 days. Before starting treatment and at each visit thereafter, the major symptoms and signs of VKC were recorded and graded as 0 (none), 1 (mild), 2 (moderate) or 3 (severe). Adverse event reports including elevation of intraocular pressure (IOP) were recorded.

Results

There were no significant differences among the groups concerning baseline mean scores of signs and symptoms, which gradually improved in all except for pannus formation in the fluorometholone group. However, all signs and symptoms (except for chemosis) were significantly less improved in the eyes of the fluorometholone group compared with the other groups at each control visit. There was significant IOP elevation after the day 3 visit in the prednisolone group only.

Conclusion

LE was as effective as prednisolone and more effective than fluorometholone, and it had no side effects during the short-term treatment of VKC patients.
Literature
1.
Ehlers WH, Donshik PC. Allergic ocular disorders: a spectrum of diseases. CLAO J. 1992;18:117–24.PubMed
2.
Abelson MB, George MA, Garofalo C. Differential diagnosis of ocular allergic disorders. Ann Allergy. 1993;70:95–109.PubMed
3.
Shoji J, Inada N, Sawa M. Antibody array-generated cytokine profiles of tears of patients with vernal keratoconjunctivitis or giant papillary conjunctivitis. Jpn J Ophthalmol. 2006;50:195–204.PubMedCrossRef
4.
Kosrirukvongs P, Visitsunthorn N, Vichyanond P, Bunnag C. Allergic conjunctivitis. Asian Pac J Allergy Immunol. 2001;19:237–44.PubMed
5.
Bonini S, Bonini S, Lambiase A, Marchi S, Pasqualetti P, Zuccaro O, et al. Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup. Ophthalmology. 2000;107:1157–63.PubMedCrossRef
6.
7.
Leonardi A. Vernal keratoconjunctivitis: pathogenesis and treatment. Prog Retin Eye Res. 2002;21:319–39.PubMedCrossRef
8.
Verin PH, Dicker ID, Mortemousque B. Nedocromil sodium eye drops are more effective than sodium cromoglycate eye drops for the long-term management of vernal keratoconjunctivitis. Clin Exp Allergy. 1999;29:529–36.PubMedCrossRef
9.
BenEzra D. Current practice: diagnosis and treatment in primary healthcare. Allergy. 1995;50:30–3.PubMedCrossRef
10.
Trocme SD, Raizman MB, Bartley GB. Medical therapy for ocular allergy. Mayo Clin Proc. 1995;67:6–9.
11.
Jerndal T, Munkby M. Corticosteroid response in dominant congenital glaucoma. Acta Ophthalmol (Copenh). 1978;56:373–83.CrossRef
12.
Pflugfelder SC, Maskin SL, Anderson B, Chodosh J, Holland EJ, De Paiva CS, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138:444–57.PubMedCrossRef
13.
Dell SJ, Lowry GM, Northcutt JA, Howes J, Novack GD, Hart K. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol. 1998;102:251–5.PubMedCrossRef
14.
Ilyas H, Slonim CB, Braswell GR, Favetta JR, Schulman M. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens. 2004;30:10–3.PubMedCrossRef
15.
Stewart R, Horwitz B, Howes J, Novack GD, Hart K. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1. J Cataract Refract Surg. 1998;24:1480–9.PubMed
16.
Friedlaender MH, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Am J Ophthalmol. 1997;123:455–64.PubMed
17.
Loteprednol Etabonate US Uveitis Study Group. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group. Am J Ophthalmol. 1999;127:537–44.CrossRef
18.
Kheirkhah A, Zavareh MK, Farzbod F, Mahbod M, Behrouz MJ. Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis. Eye (Lond). 2011;25:872–80.CrossRef
19.
Uchio E, Itoh Y, Kadonosono K. Topical bromfenac sodium for long-term management of vernal keratoconjunctivitis. Ophthalmologica. 2007;221:153–8.PubMedCrossRef
20.
Bodor N, Buchwald P. Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J. 2005;7:820–33.CrossRef
21.
Howes J, Novack GD. Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, pj-91, following chronic ocular administration. J Ocul Pharmacol Ther. 1998;14:153–8.PubMedCrossRef
22.
Wordinger RJ, Clark AF. Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma. Prog Retin Eye Res. 1999;18:629–67.PubMedCrossRef
23.
Bartlett JD, Horwitz B, Laibovitz R, Howes JF. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol. 1993;9:157–65.PubMedCrossRef
24.
Novack GD, Howes J, Crockett RS, Sherwood MB. Change in intraocular pressure during long-term use of loteprednol etabonate. J Glaucoma. 1998;7:266–9.PubMed
25.
Holland EJ, Bartlett JD, Paterno MR, Usner DW, Comstock TL. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea. 2008;27:50–5.PubMedCrossRef
26.
White EM, Macy JI, Bateman KM, Comstock TL. Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Curr Med Res Opin. 2008;24:287–96.PubMedCrossRef
27.
Bucala R, Gallati M, Manabe S, Cotlier E, Cerami A. Glucocorticoid-lens protein adducts in experimentally induced steroid cataracts. Exp Eye Res. 1985;40:853–63.PubMedCrossRef
28.
Druzgala P, Wu WM, Bodor N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res. 1991;10:933–7.PubMedCrossRef
29.
Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol. 2008;92:455–9.PubMedCrossRef
30.
Bilgihan K, Gurelik G, Akata F, Hasanreisoglu B. Fluorometholone induced cataract after photorefractive keratectomy. Ophthalmologica. 1997;211:394–6.PubMedCrossRef
31.
Costagliola C, Cati-Giovannelli B, Priccirrillo A, Delfino M. Cataracts associated with long-term topical steroids. Br J Dermatol. 1989;120:472–3.PubMedCrossRef
32.
Keklikci U, Soker SI, Sakalar YB, Unlu K, Ozekinci S, Tunik S. Efficacy of topical cyclosporin A 0.05% in conjunctival impression cytology specimens and clinical findings of severe vernal keratoconjunctivitis in children. Jpn J Ophthalmol. 2008;52:357–62.PubMedCrossRef
33.
Lambiase A, Leonardi A, Sacchetti M, Deligianni V, Sposato S, Bonini S. Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year study. J Allergy Clin Immunol. 2011;128:896–7.PubMedCrossRef
34.
Pucci N, Novembre E, Cianferoni A, Lombardi E, Bernardini R, Caputo R, et al. Effi cacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol. 2002;89:298–303.PubMedCrossRef
35.
Vichyanond P, Tantimongkolsuk C, Dumrongkigchaiporn P, Jirapongsananuruk O, Visitsunthorn N, Kosrirukvongs P. Vernal keratoconjunctivitis: result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment. J Allergy Clin Immunol. 2004;113:355–8.PubMedCrossRef
36.
Sawada S, Suzuki G, Kawase Y, Takaku F. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol. 1987;139:1797–803.PubMed
37.
Metadata
Title
Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety
Authors
Veysi Öner
Fatih Mehmet Türkcü
Mehmet Taş
Mehmet Fuat Alakuş
Yalçın İşcan
Publication date
01-07-2012
Publisher
Springer Japan
Published in
Japanese Journal of Ophthalmology / Issue 4/2012
Print ISSN: 0021-5155
Electronic ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-012-0152-5

Other articles of this Issue 4/2012

Japanese Journal of Ophthalmology 4/2012 Go to the issue

Clinical Investigation

The usefulness of infraorbital nerve enlargement on MRI imaging in clinical diagnosis of IgG4-related orbital disease

Clinical Investigation

Spatio-temporal understanding of the pathology of acute posterior multifocal placoid pigment epitheliopathy

Clinical Investigation

Comparison of efficacy of four prostaglandin analogues by bilateral treatment in healthy subjects

Clinical Investigation

Infectious causes of posterior uveitis and panuveitis in Thailand

Clinical Investigation

Risk factors for primary open-angle glaucoma in South Korea: the Namil study

Clinical Investigation

Estimating retinal nerve fiber layer thickness in normal schoolchildren with spectral-domain optical coherence tomography